| 2.49 -0.07 (-2.73%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.02  |
1-year : | 3.53 |
| Resists | First : | 2.58 |
Second : | 3.02 |
| Pivot price | 2.22 |
|||
| Supports | First : | 2.2 |
Second : | 1.97 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.2 |
| MA(100) : | 2 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.6 |
D(3) : | 75.4 |
| RSI | RSI(14): 59.6  |
|||
| 52-week | High : | 3.81 | Low : | 1.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ WHWK ] has closed below upper band by 4.2%. Bollinger Bands are 49.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.59 - 2.61 | 2.61 - 2.62 |
| Low: | 2.46 - 2.47 | 2.47 - 2.49 |
| Close: | 2.47 - 2.49 | 2.49 - 2.52 |
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Mon, 01 Dec 2025
Whitehawk therapeutics names Margaret Dugan as chief medical officer - Investing.com
Mon, 01 Dec 2025
Whitehawk Therapeutics Appoints Margaret Dugan, As Chief Medical Officer - TradingView
Mon, 01 Dec 2025
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer - PR Newswire
Wed, 26 Nov 2025
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Wed, 26 Nov 2025
Whitehawk Therapeutics (Nasdaq: WHWK) at Piper Sandler 37th Conference on Dec. 3 - Stock Titan
Tue, 11 Nov 2025
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 67.2 (%) |
| Shares Short | 978 (K) |
| Shares Short P.Month | 208 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.33 |
| Profit Margin | -108.6 % |
| Operating Margin | -754.1 % |
| Return on Assets (ttm) | -53.7 % |
| Return on Equity (ttm) | -13.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.56 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -3.9 |
| PEG Ratio | 0 |
| Price to Book value | 0.74 |
| Price to Sales | 8.16 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|